Transenterix Inc (TRXC) Sees Significant Increase in Short Interest

Transenterix Inc (NYSEAMERICAN:TRXC) was the target of a large growth in short interest in November. As of November 30th, there was short interest totalling 14,893,810 shares, a growth of 7.4% from the November 15th total of 13,862,996 shares. Based on an average daily volume of 3,705,307 shares, the days-to-cover ratio is presently 4.0 days. Currently, 10.2% of the shares of the stock are sold short.

In other news, insider Todd Pope sold 600,000 shares of the firm’s stock in a transaction on Wednesday, October 18th. The shares were sold at an average price of $3.68, for a total transaction of $2,208,000.00. Following the sale, the insider now owns 462,644 shares in the company, valued at approximately $1,702,529.92. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Joseph P. Slattery sold 333,000 shares of the firm’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $2.93, for a total transaction of $975,690.00. Following the sale, the chief financial officer now owns 440,974 shares in the company, valued at approximately $1,292,053.82. The disclosure for this sale can be found here. Insiders sold a total of 1,462,609 shares of company stock worth $4,666,595 over the last quarter.

A hedge fund recently raised its stake in Transenterix stock. Ladenburg Thalmann Financial Services Inc. boosted its position in Transenterix Inc (NYSEAMERICAN:TRXC) by 87.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 79,150 shares of the medical instruments supplier’s stock after acquiring an additional 37,000 shares during the period. Ladenburg Thalmann Financial Services Inc. owned 0.05% of Transenterix worth $113,000 at the end of the most recent reporting period.

A number of equities analysts recently commented on the stock. Ladenburg Thalmann Financial Services set a $5.00 target price on shares of Transenterix and gave the stock a “buy” rating in a research report on Friday, October 20th. Stifel Nicolaus lifted their target price on shares of Transenterix from $3.75 to $4.00 and gave the stock a “buy” rating in a research report on Tuesday, October 31st. One analyst has rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the stock. Transenterix currently has an average rating of “Hold” and a consensus target price of $2.61.

Transenterix (TRXC) opened at $2.11 on Thursday. Transenterix has a 52-week low of $0.45 and a 52-week high of $5.00.

COPYRIGHT VIOLATION WARNING: “Transenterix Inc (TRXC) Sees Significant Increase in Short Interest” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://stocknewstimes.com/2017/12/14/transenterix-inc-trxc-sees-significant-increase-in-short-interest.html.

About Transenterix

TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.

Receive News & Ratings for Transenterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply